| 1.75 0.06 (3.55%) | 07-21 12:22 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.3 | 1-year : | 2.53 |
| Resists | First : | 1.97 | Second : | 2.17 |
| Pivot price | 1.83  |
|||
| Supports | First : | 1.64 | Second : | 1.37 |
| MAs | MA(5) : | 1.74 |
MA(20) : | 1.81 |
| MA(100) : | 2.06 |
MA(250) : | 2.5 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 13.9 |
D(3) : | 16.1 |
| RSI | RSI(14): 45.3 |
|||
| 52-week | High : | 5.5 | Low : | 1.53 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ANVS ] has closed above bottom band by 28.7%. Bollinger Bands are 34.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.74 - 1.75 | 1.75 - 1.76 |
| Low: | 1.64 - 1.65 | 1.65 - 1.66 |
| Close: | 1.67 - 1.69 | 1.69 - 1.71 |
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Tue, 07 Jul 2026
Annovis enrolls 850 patients in Phase 3 Alzheimer’s study - Stock Titan
Wed, 17 Jun 2026
Annovis Bio (NYSE: ANVS) holders expand equity plan and set biennial say-on-pay - Stock Titan
Wed, 17 Jun 2026
Annovis Bio shareholders approve all proposals at annual meeting - Investing.com
Tue, 26 May 2026
Annovis Bio Regains NYSE Listing Compliance - GlobeNewswire
Wed, 20 May 2026
Annovis Bio (NYSE: ANVS) prices $15M common stock and warrant offering - Stock Titan
Tue, 19 May 2026
Annovis Bio announces public offering of stock and warrants - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 8.2 (%) |
| Held by Institutions | 16.6 (%) |
| Shares Short | 4,860 (K) |
| Shares Short P.Month | 5,020 (K) |
| EPS | -1.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.1 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -120.2 % |
| Return on Equity (ttm) | -301.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -27 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -1.08 |
| PEG Ratio | 0 |
| Price to Book value | 15.95 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|